Barclays analyst Peter Lawson lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $4 from $5 and keeps an Overweight rating on the shares. The company reported a significant fiscal 2025 guidance negative reset along with a Q1 miss, which will pressure the stock near term, but new the new guidance “looks more reasonable,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics’ Earnings Call: Mixed Sentiments and Future Prospects
- Qualcomm initiated, Lyft upgraded: Wall Street’s top analyst calls
- Iovance Biotherapeutics price target lowered to $5 from $10 at TD Cowen
- Iovance Biotherapeutics price target lowered to $25 from $30 at Chardan
- Iovance price target lowered to $20 from $32 at H.C. Wainwright